Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327854 | 0.89 | HTR6 (0.42) | HTR6FABP4PDE4BBCHEMET | |
| SCHEMBL3327961 | 0.85 | BRD4 (0.40) | HTR6PDE4BBCHERORCNR1H2 | |
| SCHEMBL3328878 | 0.85 | HDAC1 (0.41) | HTR6PDE4BBCHE | |
| SCHEMBL3327005 | 0.85 | NR1H2 (0.44) | HTR6FABP4PDE4BMETRORC | |
| SCHEMBL3327338 | 0.84 | HTR6 (0.49) | HTR6FABP4BCHERORC | |
| SCHEMBL3327322 | 0.81 | HTR6 (0.39) | HTR6FABP4 | |
| SCHEMBL28623603 | 0.79 | HTR6 (0.44) | HTR6FABP4PDE4BBCHENR1H2 | |
| SCHEMBL3325189 | 0.79 | AKR1C3 (0.40) | HTR6BCHERORCNR1H2 | |
| SCHEMBL3326736 | 0.79 | HTR6 (0.46) | HTR6PDE4BBCHE | |
| SCHEMBL3325097 | 0.78 | HTR6 (0.50) | HTR6BCHERORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | disclosed |
| EP-2155724-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008116833-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | HTR6 1/4885FABP4 873/4885PDE4B 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.